Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.
about
Complexity of immune responses to AAV transgene products - Example of factor IX.Unraveling the complex story of immune responses to AAV vectors trial after trial.Emerging Issues in AAV-Mediated In Vivo Gene Therapy.Immunomodulatory, liver depot gene therapy for Pompe disease.Pompe disease: how to solve many problems with one solution
P2860
Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Low-Dose Liver-Targeted Gene T ...... ia Immune Tolerance Induction.
@en
Low-Dose Liver-Targeted Gene T ...... ia Immune Tolerance Induction.
@nl
type
label
Low-Dose Liver-Targeted Gene T ...... ia Immune Tolerance Induction.
@en
Low-Dose Liver-Targeted Gene T ...... ia Immune Tolerance Induction.
@nl
prefLabel
Low-Dose Liver-Targeted Gene T ...... ia Immune Tolerance Induction.
@en
Low-Dose Liver-Targeted Gene T ...... ia Immune Tolerance Induction.
@nl
P2093
P2860
P1476
Low-Dose Liver-Targeted Gene T ...... ia Immune Tolerance Induction.
@en
P2093
Benjamin Arnson
Christian Leborgne
Dwight Koeberl
Federico Mingozzi
Giuseppe Ronzitti
Sang-Oh Han
Songtao Li
P2860
P304
P356
10.1016/J.OMTM.2016.12.010
P577
2017-01-11T00:00:00Z